Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
Featured trial
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.  

metastatic urothelial carcinoma
bladder cancer
bladder carcinoma
urothelial carcinoma
  • 243 views
  • 10 May, 2022
  • 64 locations
Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment

  • 18 views
  • 07 Feb, 2022
  • 13 locations
Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

treatment following surgery in adult subjects with invasive urothelial carcinoma and susceptible FGFR3 genetic alterations (mutations, and gene fusions or rearrangements) who have disease that is considered

  • 97 views
  • 16 May, 2022
  • 129 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

ascites
x-rays
chemotherapeutic agents
cellular therapy
cancer
  • 1029 views
  • 13 May, 2022
  • 103 locations
Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors (URODX-FGFR3)

This study is a case-control, propsective and muticentric clinical trial, which aim to compare the specificity and sensibility of VisioCyt urinary cytological test combined with FGFR3 mutation

bladder tumor
FGFR3
  • 0 views
  • 26 Apr, 2022
  • 1 location
  • 0 views
  • 13 May, 2022
  • 3 locations
Infigratinib in Recurrent High-Grade Glioma Patients

This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3

malignant glioma
contrast-enhanced magnetic resonance imaging
temozolomide
renal function test
calcium
  • 0 views
  • 28 Jan, 2021
  • 3 locations
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Calmette-Guerin (BCG) or chemotherapy instilled into the bladder. Participants in this study will have bladder cancer with a mutation in the FGFR3 gene. FGFR3 mutations are the most common genetic

mitomycin
bladder tumor
intravesical chemotherapy
transurethral resection
invasive bladder cancer
  • 0 views
  • 10 May, 2022
  • 7 locations
Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma

This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.

measurable disease
neutrophil count
  • 0 views
  • 13 Mar, 2022
  • 4 locations
Phase I BLASST-3 Trial ((BLASST)-3)

cancer that have mutations in FGFR3 or FGFR2 and who cannot receive chemotherapy with cisplatin prior to surgery The name of the study drug involved in this study is: Infigratinib

anticoagulants
bladder tumor
warfarin
FGFR3
hormone therapy
  • 0 views
  • 22 Apr, 2022
  • 1 location